Company Update (NASDAQ:IDRA): Idera Pharmaceuticals Inc Reports Phase 1 Data Showing Encouraging Clinical Activity of Intra-tumoral IMO-2125 in Combination with Ipilimumab

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, is reporting initial clinical data from its ongoing Phase 1/2 clinical trial of intra-tumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist.  In this arm of the Phase 1 portion of the trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma who have failed prior PD-1 therapy.  These early results indicate that IMO-2125 is demonstrating promising clinical activity and is being well tolerated in a patient population with minimal options and low expectation of clinical response with ipilimumab treatment alone.  Further clinical information from the ongoing dose escalation portion of the trial, as well as detailed information on the translational results, will be presented during an oral session at the 2016 Society for Immunotherapy of Cancer Annual Meeting beginning November 9th in Maryland.

“We have completed extensive pre-clinical work in a broad scope of tumor types to test the hypothesis of intra-tumoral administration of IMO-2125 inducing a meaningful effect on the tumor microenvironment and potentiating local and systemic tumor regression in patients.  This work gave us confidence to test the ability of IMO-2125, beginning with this current study in PD-1 refractory metastatic melanoma patients,” stated Vincent Milano, Idera’s Chief Executive Officer.

“We are energized by the early results from this ongoing trial and have been solidifying our plans to accelerate the program as we believe there is a clear path to bring IMO-2125 to melanoma patients who have not benefited from checkpoint inhibition alone and open an opportunity to establish IMO-2125 as the agent of choice to activate the tumor microenvironment and potentially improve outcomes for patients,”  Milano added. “Following a full strategic review, we have decided to prioritize the IMO-2125 program and explore strategic options for IMO-8400 in B-cell lymphoma.”

Current Data Analysis


  • 10 patients in 3 dosing cohorts (4mg, 8mg and 16mg) have been dosed and are assessable for safety, as of the September 19, 2016 cutoff date;
  • IMO-2125 in combination with ipilimumab is being generally well tolerated at all 3 dose levels studied to date;
  • Immune related adverse events have been observed in 3 subjects: 2 responding patients have experienced hypophysitis and 1 patient has discontinued the study due to a recurrence of immune related hepatitis previously observed on prior therapy with ipilimumab;
  • No dose limiting toxicities (DLTs) have been identified to date and the study is currently enrolling at the highest (32mg) dosing cohort in combination with ipilimumab.

Clinical activity

  • 6 patients treated in the first 2 dosing cohorts (4mg and 8mg) are assessable for initial clinical activity, as of the September 19, 2016 cutoff date;
  • 3 of the 4 patients with cutaneous melanoma are responders with one Complete Response (CR) and 2 Partial Responses (PR);
  • 2 patients with mucosal melanoma experienced Progressive Disease (PD).

Translational observations

  • Translational data seen through the first two dosing cohorts is promising relative to the induction of immune responses;
  • Detailed information on the translational findings from biopsies taken in the first 2 dosing cohorts and the relationship of these to clinical response is the subject of an accepted oral presentation on November 11, 2016 at the 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting by Cara Haymaker, Ph.D.,University of Texas, MD Anderson Cancer Center.

“The degree of activity we’ve seen so far in this trial is very exciting as these patients are very unlikely to respond to other therapies.  All three responses that we’ve seen are clinically meaningful, and these patients continue to do well following treatment,” statedAdi Diab, M.D., Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center.

These early results are from the Phase 1 portion of study IMO-2125-204 (NCT02644967) in which cohorts of patients with metastatic melanoma unresponsive to PD-1 inhibitor therapy are being administered escalating doses of IMO-2125 ranging from 4 mg/kg through 32 mg/kg. IMO-2125 is injected intra-tumorally into a designated tumor lesion together with a standard dosing regimen of ipilimumab given intravenously. Following determination of the recommended Phase 2 dose (RP2D) additional patients will be treated in an expansion Phase 2 portion of the study. The primary objective of the Phase 1 portion of the trial is to characterize the safety and determine a RP2D of IMO-2125 when administered intra-tumorally in combination with ipilimumab.  The primary objective of the Phase 2 portion is to assess the clinical activity of IMO-2125 in combination with ipilimumab at the respective RP2D in patients.  Assessment will be based on the immune-related response criteria (irRC) and additionally the traditional RECIST criteria.  Serial biopsies are being taken of selected injected and non-injected tumor lesions to assess immune changes and correlate with clinical response assessments.  The trial will enroll approximately 60 patients.  The study is being conducted at The University of Texas MD Anderson Cancer Center and is being led byAdi Diab, M.D., Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson as part of a strategic research alliance announced by Idera and MD Anderson in 2015.

Business Update
Idera is also reporting that the company has chosen to suspend the clinical development of IMO-8400 for B-cell lymphomas, including studies in Waldenstroms Macroglobulinemia (WM) and Diffuse Large B-Cell Lymphoma (DLBCL), and will explore strategic options in these indications.  This decision was based upon the prioritization of the clinical development plans for IMO-2125 and our assessment that the level of clinical activity seen in the WM trial does not support monotherapy, the very slow enrollment rate in DLBCL and our commercial assessment.  No safety concerns have been observed with IMO-8400 in the B-cell Lymphoma program. The development of IMO-8400 in dermatomyositis continues and is not impacted by this decision. (Original Source)

Shares of Idera Pharmaceuticals are up nearly 2% to $2.81 in pre-market trading. IDRA has a 1-year high of $4.42 and a 1-year low of $1.19. The stock’s 50-day moving average is $2.07 and its 200-day moving average is $1.78.

On the ratings front, Wedbush analyst Heather Behanna reiterated a Buy rating on IDRA, with a price target of $6, in a report issued on August 25. The current price target implies an upside of 117.4% from current levels. According to, Behanna has a yearly average return of 15.7%, a 47.5% success rate, and is ranked #506 out of 4183 analysts.

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts